STAT3 gene polymorphisms and susceptibility to non-small cell lung cancer

Genetics and Molecular Research

Volumn 10, Issue 3, 2011, Pages 1856-1865

  Jiang, B ^a   Zhu, Z Z ^b   Liu, F ^c   Yang, L J ^d   Zhang, W Y ^c   Yuan, H H ^c   Wang, J G ^c   Hu, X H ^c   Huang, G ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b No 113 Hospital of People's Liberation Army   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Non small cell lung cancer; Polymorphisms; STAT3

Indexed keywords

STAT3 PROTEIN;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CHINESE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STAT3 GENE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; RISK FACTORS; SIGNAL TRANSDUCTION; SMOKING; STAT3 TRANSCRIPTION FACTOR;

EID: 80955141269     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/vol10-3gmr1071     Document Type: Article

References (35)

1. Abdulghani J, Gu L, Dagvadorj A, Lutz J, et al. (2008). Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172: 1717-1728.
2. Barrett JC, Fry B, Maller J and Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
3. Barrett JC, Hansoul S, Nicolae DL, Cho JH, et al. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40: 955-962.
4. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, et al. (2009). gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15: 91-102.
5. Bowman T, Garcia R, Turkson J and Jove R (2000). STATs in oncogenesis. Oncogene 19: 2474-2488.
6. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, et al. (1999). Stat3 as an oncogene. Cell 98: 295-303.
7. Darnell JE (2005). Validating Stat3 in cancer therapy. Nat. Med. 11: 595-596.
8. Dauer DJ, Ferraro B, Song L, Yu B, et al. (2005). Stat3 regulates genes common to both wound healing and cancer. Oncogene 24: 3397-3408.
9. Ferguson LR, Han DY, Fraser AG, Huebner C, et al. (2010). Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat. Res. 690: 108-115.
10. Fletcher S, Drewry JA, Shahani VM, Page BD, et al. (2009). Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem. Cell Biol. 87: 825-833.
11. Grivennikov SI and Karin M (2010). Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21: 11-19.
12. Horinaga M, Okita H, Nakashima J, Kanao K, et al. (2005). Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology 66: 671-675.
13. Hsieh FC, Cheng G and Lin J (2005). Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem. Biophys. Res. Commun. 335: 292-299.
14. Hsu HS, Huang PI, Chang YL, Tzao C, et al. (2011). Cucurbitacin i inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 117: 2970-2985.
15. Ito N, Eto M, Nakamura E, Takahashi A, et al. (2007). STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25: 2785-2791.
16. Jing N, Zhu Q, Yuan P, Li Y, et al. (2006). Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol. Cancer Ther. 5: 279-286.
17. Karin M (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
18. Kreil S, Waghorn K, Ernst T, Chase A, et al. (2010). A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon alpha. Haematologica 95: 148-152.
19. Lai SY and Johnson FM (2010). Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist. Updat. 13: 67-78.
20. Lin Q, Lai R, Chirieac LR, Li C, et al. (2005). Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am. J. Pathol. 167: 969-980.
21. Parkin DM, Bray F, Ferlay J and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108.
22. Sansone P, Storci G, Tavolari S, Guarnieri T, et al. (2007). IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117: 3988-4002.
23. Scagliotti GV, Longo M and Novello S (2009). Nonsmall cell lung cancer in never smokers. Curr. Opin. Oncol. 21: 99-104.
24. Shields PG (2002). Molecular epidemiology of smoking and lung cancer. Oncogene 21: 6870-6876.
25. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, et al. (2007a). Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 104: 7391-7396.
26. Siddiquee KA, Gunning PT, Glenn M, Katt WP, et al. (2007b). An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem. Biol. 2: 787-798.
27. Stephens M, Smith NJ and Donnelly P (2001). A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68: 978-989.
28. Turkson J (2004). STAT proteins as novel targets for cancer drug discovery. Expert. Opin. Ther. Targets. 8: 409-422.
29. Vaclavicek A, Bermejo JL, Schmutzler RK, Sutter C, et al. (2007). Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocr. Relat. Cancer 14: 267-277.
30. Weerasinghe P, Garcia GE, Zhu Q, Yuan P, et al. (2007). Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int. J. Oncol. 31: 129-136.
31. Yang L, Parkin DM, Li LD, Chen YD, et al. (2004). Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br. J. Cancer 90: 2157-2166.
32. Yin W, Cheepala S, Roberts JN, Syson-Chan K, et al. (2006). Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol. Cancer 5: 15.
33. Yin ZJ, Jin FG, Liu TG, Fu EQ, et al. (2010). Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells. J. Surg. Res.Doi: 10.1016/j.jss.2010.03.053.
34. Yu H and Jove R (2004). The STATs of cancer -new molecular targets come of age. Nat. Rev. Cancer 4: 97-105.
35. Yu H, Pardoll D and Jove R (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9: 798-809.